2012 TAG Update
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
Micardis Sign-on Letter to Boehringer Ingelheim
Letter urging the company to reconsider its negative decision to provide free telmisartan (Micardis) and matching placebo to the AIDS Clinical Trials Group so that it may move forward with Study A5317.
Cure-Related Research at AIDS 2012
By Richard Jefferys At the recent International AIDS Conference in Washington, D.C. (AIDS 2012), the research effort to develop a cure for HIV infection attained a higher profile than it ever has in the past. At a press conference on…
Only Stronger U.S. Leadership Can End the AIDS Epidemic
Existing treatment and prevention techniques could prevent millions of new HIV infections and deaths from AIDS—but only if Obama sustains funding. By Mark Harrington This article was first published on 24 July 2012 in theAtlantic.com. Four years ago, President Obama's…
TAG at 20 – Part II: On a Darkling Plain—The Years of Despair
Before the Discovery of HAART By Mark Harrington And we are here as on a darkling plain Swept with confused alarms of struggle and flight, Where ignorant armies clash by night. —Matthew Arnold, “Dover Beach”[i] This is the second in…
TAGline Fall 2012
TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement
Mark Harrington Tribute to Médecins Sans Frontières (MSF)
In 2012, the Fulbright Association presented its J. William Fulbright Prize for International Understanding to Médecins Sans Frontières (MSF); the first time this was awarded to an organization, not an individual. Treatment Action Group’s executive director, Mark Harrington, delivered this…
HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps between Scientific Promise and Program Delivery
On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.
2012 Pipeline Report
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.
Letter to NIAID Director Anthony Fauci Opposing the HVTN 505 Vaccine Trial
TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.